Combined Lung Cancer Treatment Yielded Positive Results
A phase 1b study showed high response rates for patients using tegavivint and osimertinib to combat lung cancer.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Should medical research prioritize funding for combination therapies to overcome cancer drug resistance?
In 2026, researchers reported that a combination therapy of tegavivint and osimertinib produced an objective response rate of 79% in 19 evaluable patients with NSCLC. The study identified an 8 mg/kg dose for tegavivint, demonstrating potential for treating drug-tolerant cancer cells.
Why it matters
The study addresses a critical challenge in oncology where EGFR-mutated NSCLC cells survive standard treatment through drug-tolerant persister cells. By inhibiting the beta-catenin pathway, this combination therapy offers a new approach to overcoming resistance and extending patient survival.
The study recorded a 79% objective response rate and a median progression-free survival of 19.9 months, with no dose-limiting toxicities observed at the 8 mg/kg level. Patients exhibited a mean tumor burden decrease of 65%.
The players
ASCO
The American Society of Clinical Oncology is a professional organization representing physicians and oncology professionals who care for people living with cancer.
The details
Patients in the study received 80 mg of osimertinib daily combined with weekly intravenous doses of tegavivint for four months. Tegavivint works by binding to transducin beta-like protein 1 to inhibit Wnt/beta-catenin signaling, which is known to drive the survival of persistent cancer cells.
Timeline
Data from the clinical study were presented at the 2026 ASCO Annual Meeting.
The Big Picture
This study follows the established safety and dosage protocols outlined in the NCT04780568 clinical trial program. The reported outcomes extend the efficacy data previously gathered under this specific research investigation.
The successful identification of a recommended dose provides a foundation for future treatment strategies for patients with EGFR-mutated lung cancer. While promising, the therapy remains subject to further clinical validation before it is available for general patient use.
The takeaway
This research highlights the importance of targeting drug-tolerant pathways to improve outcomes in advanced lung cancer cases. Patients should consult with their oncologists about current clinical trial opportunities for combination therapies targeting Wnt/beta-catenin signaling.
Further reading
Learn more about the latest research and developments in Cancer.
Live Poll
Should medical research prioritize funding for combination therapies to overcome cancer drug resistance?
